Endothelial-cell activation describes changes in the cells lining blood vessels that alter migration, proliferation, survival, barrier behavior, adhesion molecules, and formation of new vascular structures. MSCs and MSC-derived extracellular vesicles can release signals that influence endothelial behavior in experimental systems. Depending on context, these signals may support repair after ischemia or injury, but endothelial activation can also participate in inflammation and abnormal vascular growth. Tube-formation assays and endothelial proliferation assays are useful mechanistic models but do not reproduce the full complexity of blood-vessel formation in vivo. A credible angiogenic mechanism therefore requires evidence extending beyond a single in-vitro endothelial assay.
Figure 1 placeholder — Endothelial-cell activation
Vascular growth factors
Vascular growth factors are signaling molecules that regulate endothelial survival, migration, proliferation, permeability, and vessel formation. Vascular endothelial growth factor (VEGF), fibroblast growth factors, angiopoietins, hepatocyte growth factor, platelet-derived growth factor, and other mediators may contribute to MSC- or EV-associated angiogenic signaling. Their effects depend on concentration, timing, receptor expression, tissue oxygenation, inflammation, and interactions with extracellular matrix. Measuring a growth factor in conditioned medium or EV preparations demonstrates presence, not functional sufficiency. Angiogenesis is produced by coordinated signaling networks rather than by one molecule in isolation.
Figure 2 placeholder — Vascular growth factors
Pericyte interactions
Pericyte interactions involve communication between endothelial cells and mural cells that surround capillaries and small vessels. Pericytes help regulate vascular stability, endothelial survival, barrier function, basement-membrane organization, and microvascular remodeling. MSCs share some phenotypic and functional features with perivascular stromal cells, but the terms MSC and pericyte are not interchangeable. Experimental MSC or EV signals may influence pericyte recruitment, survival, or communication with endothelium. Demonstrating clinically meaningful vascular repair requires evidence of organized vessel function, not merely increased numbers of endothelial structures.
Figure 3 placeholder — Pericyte interactions
Vessel maturation
Vessel maturation is the transition from newly formed, fragile endothelial sprouts toward more stable and functional vascular networks. Maturation involves endothelial junctions, pericyte or smooth-muscle-cell coverage, basement-membrane deposition, extracellular-matrix organization, appropriate perfusion, and pruning of unstable vessels. Increased microvessel density does not necessarily mean improved tissue perfusion; newly formed vessels may be immature, leaky, poorly connected, or nonfunctional. Mechanistic studies should therefore distinguish angiogenic sprouting from durable vascular stabilization and should measure perfusion or other functional vascular endpoints when possible.
Figure 4 placeholder — Vessel maturation
Pathological angiogenesis risks
Pathological angiogenesis risks arise when vascular growth occurs in an unwanted location, at an inappropriate magnitude, or in support of disease. Excessive angiogenic signaling can contribute to tumor vascularization, proliferative retinopathies, some inflammatory disorders, vascular malformations, and other pathological processes. Because MSCs and EVs can carry proangiogenic as well as antiangiogenic signals, the net effect is product- and context-dependent. A mechanism considered beneficial in ischemic tissue could be undesirable in a patient with an active malignancy or another angiogenesis-sensitive condition. Safety assessment should therefore consider both insufficient and excessive vascular responses.
Figure 5 placeholder — Pathological angiogenesis risks
Clinical takeaway
Angiogenesis is not simply 'making more blood vessels.' Effective vascular repair requires coordinated endothelial activation, growth-factor signaling, support-cell interactions, vessel maturation, and functional perfusion while avoiding pathological vascular growth.
Hypoxia and angiogenic signaling
Low oxygen can activate hypoxia-inducible pathways that change the secretion of VEGF and other angiogenic mediators. Hypoxic preconditioning may alter MSC or EV products, but a stronger angiogenic laboratory signal does not automatically establish a superior clinical product.
Sprouting versus perfusion
Angiogenic sprouting is an early structural event. Functional benefit requires vessels that connect to the circulation, carry blood appropriately, maintain barrier integrity, and support tissue metabolism.
Dose and timing
Angiogenic signals can have different effects according to concentration and timing. Too little signaling may fail to support repair, whereas excessive or prolonged signaling may produce leaky, disorganized, or pathological vessels.
Product specificity
Cell source, donor, culture conditions, passage, oxygen tension, stimulation, EV composition, separation, formulation, and dose can all change angiogenic activity. Results should not be generalized automatically across products.
Potency assays
An angiogenic potency assay may measure endothelial migration, proliferation, tube formation, receptor signaling, or another relevant function. Such assays can support product characterization but do not by themselves prove improved tissue perfusion or clinical benefit.
Clinical interpretation
An increase in VEGF, endothelial markers, capillary density, or tube formation supports a mechanistic hypothesis. It does not establish durable vascular function, improved organ performance, or patient benefit.
Knowledge gaps
For many investigational MSC and EV products, the relative contributions of endothelial signaling, pericytes, vessel maturation, and host vascular biology remain incompletely defined in humans.
Bottom-line evidence statement
Angiogenesis is a coordinated and context-dependent process. Strong evidence distinguishes new vascular structures from mature functional perfusion and evaluates both potential benefit and pathological angiogenesis risk.
Additional controlled terminology
Angiogenesis begins with responses of an endothelial cell and can involve vascular endothelial growth factor, fibroblast growth factor, angiopoietin, hepatocyte growth factor, and platelet-derived growth factor. Endothelial migration and endothelial proliferation are often assessed with a tube-formation assay or related models. A pericyte is a mural cell associated with microvessels and contributes to basement membrane organization and microvascular remodeling. Angiogenic sprouting and microvessel density do not establish vascular permeability, perfusion, or vascular stabilization. Hypoxia can signal through hypoxia-inducible factor pathways. Safety concerns include tumor angiogenesis and proliferative retinopathy when proangiogenic signaling is inappropriate. An angiogenic potency assay should measure product-relevant biological activity without being mistaken for clinical effectiveness.